This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Interventions
Lenalidomide added to BSC without erythropoeitin (EPO) was compared with BSC with EPO. Oral lenalidomide was given at a dose of 10 mg, either daily or for 21 days every 4 weeks (dosage was reduced to 5 mg daily in the majority of patients during the course of treatment). The standard weekly maintenance dose for the comparator group was 35.000 IU EPO and 375 μg granulocyte-colony stimulating factor.
Location/setting
USA/secondary care.
Methods

Analytical approach:
A decision modelling analysis was undertaken to simulate the clinical and economic outcomes associated with the two strategies under examination. The time horizon of the analysis was 1 year. The perspective was reported to have been that of a US health care payer.
Effectiveness data:
The clinical data appear to have been derived from the published literature, based on a selection of known studies, since details of a review of the literature were not reported. Key data on lenalidomide were derived from a pivotal multicentre phase II clinical trial, while key clinical data on BSC with EPO came from an observational cohort study. The main clinical effectiveness estimates were the rate and duration of transfusion independence.
Monetary benefit and utility valuations:
Face-to-face interviews with a group of 8 MDS patients in the US were carried out to elicit utility weights based on the time trade-off method.
Measure of benefit:
The summary benefit measures were transfusion-free years (TFYs) and quality-adjusted life-years (QALYs). uncertainty was well addressed, although it was mainly restricted to key model inputs. The issue of generalisability was discussed and the authors pointed out that caution is required when extrapolating these findings given the limited availability of clinical data. However, the use of wide ranges of values in the sensitivity analysis enhances the external validity of the study results. Overall, there was little information on the decision model and no graphical depiction. A longer follow-up period would have been more appropriate to capture the full impact of the treatment, as the authors acknowledged. However, the choice of a 1-year follow up was justified by the data availability from a phase II trial, the fast track designation status of lenalidomide, and the lack of data to inform longer-term extrapolation of the trial results.
Concluding remark:
: The methodology of the study appears to have been sound and clearly reported. The selection of the key model inputs was justified and appropriate, despite the poor reporting of the decision model. The conclusions reached by the authors were robust.
